VRAYLAR schizophrenia safety

Most common adverse reactions from short-term schizophrenia studies (≥5% and at least twice that of placebo)1

>97% of EPS and akathisia events in short-term schizophrenia studies were mild or moderate2

*Data shown from baseline to endpoint (Week 6) by modal daily dose, defined as most frequently administered dose per patient.1

EPS included bradykinesia, cogwheel rigidity, drooling, dyskinesia, dystonia, extrapyramidal disorder, hypokinesia, masked facies, muscle rigidity, muscle tightness, musculoskeletal stiffness, oculogyric crisis, oromandibular dystonia, parkinsonism, salivary hypersecretion, tardive dyskinesia, torticollis, tremor, and trismus.1

EPS=extrapyramidal symptoms.

Discontinuation rates1,2

Overall, 9% of the patients who received VRAYLAR discontinued treatment due to an adverse reaction, compared with 12% of placebo-treated patients in these trials.

  • These data include patients who discontinued due to worsening of schizophrenia (ie, untreated illness)

Monitor patients when initiating or changing the dose of VRAYLAR.1

EPS and akathisia are among the most common adverse reactions and are most frequently observed upon initiation and up-titration.1,2